Structural basis for allosteric PARP-1 retention on DNA breaks
暂无分享,去创建一个
S. Pettitt | C. Lord | B. E. Black | J. Pascal | T. Talele | Uday Kiran Velagapudi | M. A. Hancock | Dragomir B. Krastev | Levani Zandarashvili | M. Langelier | J. Steffen | D. Krastev | Andrew J. Wicks | Ramya Billur | Zain M Hannan | M. Hancock
[1] A. Ashworth,et al. PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer , 2019, The Journal of clinical investigation.
[2] S. C. Panchal,et al. PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow , 2018, Molecular Cancer Research.
[3] A. Ashworth,et al. Synthetic lethal therapies for cancer: what’s next after PARP inhibitors? , 2018, Nature Reviews Clinical Oncology.
[4] A. Ashworth,et al. Coupling bimolecular PARylation biosensors with genetic screens to identify PARylation targets , 2018, Nature Communications.
[5] W. Symmans,et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. , 2018, The Lancet. Oncology.
[6] B. E. Black,et al. NAD+ analog reveals PARP-1 substrate-blocking mechanism and allosteric communication from catalytic center to DNA-binding domains , 2018, Nature Communications.
[7] Simon C Watkins,et al. PARP1 changes from three-dimensional DNA damage searching to one-dimensional diffusion after auto-PARylation or in the presence of APE1 , 2017, Nucleic acids research.
[8] A. Ashworth,et al. Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance , 2017, bioRxiv.
[9] A. Heijink,et al. Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells , 2017, Nature Communications.
[10] A. Ashworth,et al. Modeling Therapy Resistance in BRCA1/2-Mutant Cancers , 2017, Molecular Cancer Therapeutics.
[11] Alan Ashworth,et al. PARP inhibitors: Synthetic lethality in the clinic , 2017, Science.
[12] Ziying Liu,et al. PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes , 2017, Genes & development.
[13] Y. Pommier,et al. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action , 2016, Science Translational Medicine.
[14] Yonghao Yu,et al. Chemical genetic discovery of PARP targets reveals a role for PARP-1 in transcription elongation , 2016, Science.
[15] J. Pascal,et al. Structural Basis of Detection and Signaling of DNA Single-Strand Breaks by Human PARP-1 , 2015, Molecular cell.
[16] Jamin D Steffen,et al. PARP-1 Activation Requires Local Unfolding of an Autoinhibitory Domain. , 2015, Molecular cell.
[17] T. Ellenberger,et al. The rise and fall of poly(ADP-ribose): An enzymatic perspective. , 2015, DNA Repair.
[18] Yan Shi,et al. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors , 2015, Molecular Cancer Research.
[19] B. Wang,et al. Trapping Poly(ADP-Ribose) Polymerase , 2015, The Journal of Pharmacology and Experimental Therapeutics.
[20] E. Pai,et al. Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2 , 2014, Acta crystallographica. Section D, Biological crystallography.
[21] G. Sica,et al. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer , 2014, Cancer medicine.
[22] J. Pascal,et al. PARP-2 and PARP-3 are selectively activated by 5′ phosphorylated DNA breaks through an allosteric regulatory mechanism shared with PARP-1 , 2014, Nucleic acids research.
[23] James H. Doroshow,et al. Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic Inhibition , 2014, The Journal of Pharmacology and Experimental Therapeutics.
[24] Y. Pommier,et al. Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib , 2013, Molecular Cancer Therapeutics.
[25] A. Ashworth,et al. BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency , 2013, Clinical Cancer Research.
[26] J. Pascal,et al. PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis. , 2013, Current opinion in structural biology.
[27] Y. Pommier,et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. , 2012, Cancer research.
[28] J. Pascal,et al. Structural Basis for DNA Damage–Dependent Poly(ADP-ribosyl)ation by Human PARP-1 , 2012, Science.
[29] R. Martínez-Zamudio,et al. Histone ADP-Ribosylation Facilitates Gene Transcription by Directly Remodeling Nucleosomes , 2012, Molecular and Cellular Biology.
[30] R. Hromas,et al. Synthetic lethality: exploiting the addiction of cancer to DNA repair. , 2011, Blood.
[31] A. Ashworth,et al. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations , 2011, Cell cycle.
[32] N. Pannu,et al. REFMAC5 for the refinement of macromolecular crystal structures , 2011, Acta crystallographica. Section D, Biological crystallography.
[33] Randy J. Read,et al. Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.
[34] J. Pascal,et al. Crystal Structures of Poly(ADP-ribose) Polymerase-1 (PARP-1) Zinc Fingers Bound to DNA , 2011, The Journal of Biological Chemistry.
[35] H. Kotani,et al. Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements , 2010, Human Genetics.
[36] J. Pascal,et al. The Zn3 Domain of Human Poly(ADP-ribose) Polymerase-1 (PARP-1) Functions in Both DNA-dependent Poly(ADP-ribose) Synthesis Activity and Chromatin Compaction* , 2010, The Journal of Biological Chemistry.
[37] S. Kaufmann,et al. PARP inhibition: PARP1 and beyond , 2010, Nature Reviews Cancer.
[38] P. Emsley,et al. Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.
[39] Randy J. Read,et al. Acta Crystallographica Section D Biological , 2003 .
[40] Eric F. Johnson,et al. Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. , 2009, Journal of medicinal chemistry.
[41] A. Ashworth,et al. A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. , 2008, DNA repair.
[42] Randy J. Read,et al. Phaser crystallographic software , 2007, Journal of applied crystallography.
[43] P. Katsamba,et al. Analyzing a kinetic titration series using affinity biosensors. , 2006, Analytical biochemistry.
[44] H. Leonhardt,et al. Recruitment of DNA methyltransferase I to DNA repair sites. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[45] Csaba Szabó,et al. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors , 2005, Nature Reviews Drug Discovery.
[46] M. Y. Kim,et al. NAD+-Dependent Modulation of Chromatin Structure and Transcription by Nucleosome Binding Properties of PARP-1 , 2004, Cell.
[47] Csaba Szabó,et al. The discovery and synthesis of novel adenosine substituted 2,3-dihydro-1H-isoindol-1-ones: potent inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1). , 2004, Bioorganic & medicinal chemistry letters.
[48] P. Chambon,et al. Functional interaction between PARP‐1 and PARP‐2 in chromosome stability and embryonic development in mouse , 2003, The EMBO journal.
[49] K. Schlemmer,et al. Substituted Uracil Derivatives as Potent Inhibitors of Poly(ADP‐ribose)polymerase‐1 (PARP‐1) , 2003 .
[50] A. Spradling,et al. Chromatin Loosening by Poly(ADP)-Ribose Polymerase (PARP) at Drosophila Puff Loci , 2003, Science.
[51] G. Poirier,et al. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. , 1999, The Biochemical journal.
[52] D. Myszka,et al. Improving biosensor analysis , 1999, Journal of molecular recognition : JMR.
[53] Masahiko S. Satoh,et al. Role of poly(ADP-ribose) formation in DNA repair , 1992, Nature.
[54] S. Kaufmann,et al. PARP inhibition: PARP1 and beyond , 2010, Nature Reviews Cancer.